Answer
Durvalumab (Imfinzi) can cause immune-mediated hypothyroidism, hyperthyroidism and thyroiditis, and hypothyroidism may follow hyperthyroidism.
Sources for this answer
- IMFINZI 50 mg/mL concentrate for solution for infusionAstraZeneca UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 38Document updated
Sources checked